Polyene phosphatidylcholine injection in the treatment of alcoholic liver disease:a systematic review and Meta-analysis
10.12173/j.issn.1008-049X.202310125
- VernacularTitle:多烯磷脂酰胆碱注射液治疗酒精性肝病的系统评价与Meta分析
- Author:
Baoqi ZENG
1
,
2
,
3
;
Meng ZHANG
;
Xiaozhi LIU
;
Feng SHENG
;
Feng SUN
Author Information
1. 天津市第五中心医院(北京大学滨海医院)中心实验室(天津 300450)
2. 北京大学公共卫生学院流行病与卫生统计学系(北京 100191)
3. 重大疾病流行病学教育部重点实验室(北京大学)(北京 100191)
- Keywords:
Polyene phosphatidylcholine;
Alcoholic liver disease;
Efficacy;
Meta-analysis;
Randomized controlled trial
- From:
China Pharmacist
2024;27(1):135-144
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of polyene phosphatidylcholine injection in the treatment of liver disease.Methods Pubmed,Embase,The Cochrane Library,ClinicalTrial.gov,CNKI,SinoMed,VIP,and WanFang Data were electronically searched to collect randomized controlled trials(RCTs)of polyene phosphatidylcholine injection in the treatment of liver disease from inception to December 31st,2022.Two researchers independently screened literature,extracted data and assessed the risk of bias of the included studies.The Meta-analysis was performed using Stata 17.0 software.Results A total of 10 RCTs were included,including 809 patients.Meta-analysis showed that the effective rate in the polyene phosphatidylcholine injection group was higher than that in the control group(RR=1.12,95％CI 1.04 to 1.20,P=0.003 8).Compared with the control group,polyene phosphatidylcholine injection could decrease ALT level(MD=-18.92 U/L,95％CI-27.75 to-10.09,P＜0.001),AST level(MD=-31.19 U/L,95％CI-46.27 to-16.11,P=0.000 1),TBiL level(MD=-7.31 μmol/L,95％CI-10.75 to-3.88,P＜0.001),and GGT levels(MD=-48.93 U/L,95％CI-54.64 to-43.21,P＜0.001).Only one study reported mild adverse events,and six studies reported no severe adverse events in patients.Conclusion Current evidence shows that polyene phosphatidylcholine injection in the treatment of alcoholic liver disease can increase the effective rate,improve the levels of liver function indicators(ALT,AST,TBiL,and GGT),and has less adverse events.Due to the limited number and quality of included studies,the above conclusions need to be verified by more high-quality studies.
